Heidelberg Pharma GmbH is a pharmaceutical company with a dual business model: (A) Providing preclinical drug development services in general with a special focus on the development of ADCs. Heidelberg Pharma has ample experience in providing antibody-drug conjugate related services to its clients. (B) Development of novel therapeutics in oncology based on its own proprietary 2nd generation ADC technology based on a novel toxin.
ADC Bio is an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of ADCs. The company are specialists in state-of-the-art bio-conjugation techniques and cytotoxin drug-linker synthesis, assisting drug developers to deliver their next generation ADCs. Our proprietary ‘Lock-Release’ technology aims to become a new paradigm in the way ADCs are developed and manufactured by providing fast, simple and robust conjugation processes. www.adcbio.com
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical… Read more
BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, ADCs , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.
CordenPharma is a leader in the development and manufacturing of highly potent warheads and linkers for ADCs. From its two facilities CordenPharma Boulder and CordenPharma Colorado, both in Boulder, Colorado, CordenPharma offers development and manufacturing services for clinical and commercial supply of highly potent small molecules, including peptides (solution & solid phase). Both facilities have over 25 years of experience with highly potent compounds and the demonstrated ability to safely work with products <1ng/m3 OEL.
Heraeus, the precious metals and technology group headquartered in Hanau, Germany, is a global, private company with 160 years of tradition. Our fields of competence include precious metals, materials, and technologies, sensors, biomaterials, and medical products, as well as dental products, quartz glass, and specialty light sources. With product revenues of €4.1 billion and precious metal trading revenues of €17.9 billion, as well as more than 12,900 employees in over 120 subsidiaries worldwide, Heraeus holds a leading position in its global markets.
The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute-designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development. www.jax.org
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies
MilliporeSigma, a life science leader, is a business of Merck KGaA, Darmstadt, Germany, providing services as a strategic partner to help advance the promise of life saving therapies. With the acquisition of Sigma-Aldrich (SAFC), we now have the largest offering of products and contract manufacturing services for formulations, actives and biotechnology processes. Our joint ADC offering now includes a full range of services that spans conjugation, mAbs, linkers and payloads, process development, and much more
Piramal Pharma Solution’s Antibody Drug Conjugate Business is one of the world’s leading contract development and manufacturing sites delivering early and late phase clinical and commercial supplies. Our flexible manufacturing regime and dedication to ADC processing is why our clients choose Piramal as their preferred partner. We seek to reduce the complexity associated with ADC processing allowing for integrated and seamless scale-up of each unique ADC program, including fill finish.